We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock

Delisted

PSTX was delisted on the 7th of January, 2025.

96 hedge funds and large institutions have $153M invested in Poseida Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,282% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $88K

71% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 21

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

3% more funds holding

Funds holding: 9396 (+3)

1% less capital invested

Capital invested by funds: $155M → $153M (-$1.56M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
96
Holders Change
+3
Holders Change %
+3.23%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
16
Increased
36
Reduced
21
Closed
13
Calls
$1.22M
Puts
$88K
Net Calls
+$1.13M
Net Calls Change
-$20K
Name Holding Trade Value Shares
Change
Change in
Stake
Principal Financial Group
101
Principal Financial Group
Iowa
-$35.1K -12,006 Closed
GCM
102
Graham Capital Management
Connecticut
-$32.1K -11,004 Closed
Verition Fund Management
103
Verition Fund Management
Connecticut
-$31.2K -10,673 Closed
Group One Trading
104
Group One Trading
Illinois
-$28.5K -9,216 Closed
CBT
105
Central Bank & Trust
Kentucky
-$22.2K -7,608 Closed
US Bancorp
106
US Bancorp
Minnesota
-$15.2K -5,200 Closed
Simplex Trading
107
Simplex Trading
Illinois
-$4.13K -1,335 Closed
NC
108
nVerses Capital
Florida
-$2.34K -800 Closed
Lazard Asset Management
109
Lazard Asset Management
New York
-$628 -203 -61%

PSTX Hedge Fund Activity: Q3 2024 in Review

96 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2024, worth a combined $153M — down 1% from $155M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new PSTX positions and 13 closed out — a net gain of 3 holders — while 36 added to existing stakes and 21 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.8M. The largest seller was Boxer Capital, cutting an estimated $7.66M.

  • 96 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2024, up from 93 in Q2 2024.
  • Funds reported $153M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2024, down 1% quarter-over-quarter.
  • 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2024 and 13 closed out, a net change of +3 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2024 was Millennium Management, an estimated $4.8M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2024 was Boxer Capital, an estimated $7.66M sold.

Based on aggregated 13F filings for Q3 2024.